Literature DB >> 8971833

Embolization of the nidus of brain arteriovenous malformations with n-butyl cyanoacrylate.

G M Debrun1, V Aletich, J I Ausman, F Charbel, M Dujovny.   

Abstract

OBJECTIVE: To demonstrate that nidus embolization of brain arteriovenous malformations (AVMs) with Histoacryl (B. Braun, Melsungen, Germany) is effective and yields low morbidity and mortality rates.
METHODS: We present a retrospective analysis of 54 brain AVMs treated at the University of Illinois at Chicago from April 1994 to December 1995. Treatment modalities included embolization in all cases and then surgical resection or radiosurgery. INSTRUMENTATION: The nidus was reached with the combined use of a Magic microcatheter (Balt, Montmorency, France) and a Terumo 0.010-inch guidewire. TECHNIQUE: Embolization was performed only when the tip of the microcatheter was wedged into the nidus of the AVMs with no reflux of contrast proximally. The embolization was performed using simultaneous biplane roadmapping with the patient under general anesthesia without Amytal testing.
RESULTS: Twenty-six of 54 patients are still waiting for more radical treatment. Two deaths and two minor and one severe permanent neurological deficit occurred. Three patients were cured with embolization alone; 11 patients were cured after surgical resection. Three patients underwent radiosurgery, with one cure after 1 year.
CONCLUSION: Nidus embolization with Histoacryl is an effective technique that permits complete cure of a large number of brain AVMs, with or without surgical resection and/or radiosurgery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8971833

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  50 in total

1.  Embolization of arteriovenous malformations prior to radiosurgery.

Authors:  S Miyachi; M Negoro; R Okamoto; G Otsuka; O Suzuki; J Yoshida
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

2.  Endovascular treatment of brain arteriovenous malformations: the toronto experience.

Authors:  P Klurfan; T Gunnarsson; C Haw; K G Ter Brugge
Journal:  Interv Neuroradiol       Date:  2005-10-27       Impact factor: 1.610

3.  Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions.

Authors:  Mario L Fabiilli; James A Lee; Oliver D Kripfgans; Paul L Carson; J Brian Fowlkes
Journal:  Pharm Res       Date:  2010-09-25       Impact factor: 4.200

4.  Embolization of an AVM with acrylic glue through a new microcatheter with detachable tip: an amazing experience.

Authors:  M Halil Oztürk; Hüseyin Unal; Hasan Dinç
Journal:  Neuroradiology       Date:  2008-08-13       Impact factor: 2.804

5.  Management of brain arteriovenous malformations.

Authors:  Sherri A Braksick; Jennifer E Fugate
Journal:  Curr Treat Options Neurol       Date:  2015-07       Impact factor: 3.598

6.  In vivo assessment of chitosan/β-glycerophosphate as a new liquid embolic agent.

Authors:  Y Wang; N Xu; Q Luo; Y Li; L Sun; H Wang; K Xu; B Wang; Y Zhen
Journal:  Interv Neuroradiol       Date:  2011-04-29       Impact factor: 1.610

7.  Transarterial Wedged-catheter, Flow-arrest, N-butyl Cyanoacrylate Embolization of Three Dural Arteriovenous Fistulae in a Single Patient.

Authors:  S M Russell; H H Woo; P K Nelson
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

Review 8.  Endovascular management of arteriovenous malformations of the brain.

Authors:  Charles A Bruno; Philip M Meyers
Journal:  Interv Neurol       Date:  2013-09

9.  Predictors of total obliteration in endovascular treatment of cerebral arteriovenous malformations.

Authors:  José Antonio Jordan; Juan Carlos Llibre; Frank Vazquez; Raul Marino Rodríguez
Journal:  Neuroradiol J       Date:  2014-02-24

10.  Predictors of hemorrhagic complications from endovascular treatment of cerebral arteriovenous malformations.

Authors:  José A Jordan; Juan Carlos Llibre; Frank Vázquez; Raúl Rodríguez; José A Prince; José Carlos Ugarte
Journal:  Interv Neuroradiol       Date:  2014-02-10       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.